Browsing all 8 trials, sorted by Recently updated.
- NCT05021536 Phase 3 Completed
AMX0035 in ALS (CENTAUR / PHOENIX)
ALS (no genetic stratification)
PHOENIX failed primary; Relyvrio voluntarily withdrawn April 2024. Triggered post-hoc reflection on Phase 2 effect-size inflation.
ClinicalTrials.gov ↗ - NCT02642393 Phase 3 Completed
Inosine in Early Parkinson's Disease (SURE-PD3)
Early Parkinson's Disease
Failed primary endpoint despite Mendelian-randomization support for urate→PD; classic example of MR-justified target failing in trial.
ClinicalTrials.gov ↗ - NCT03761849 Phase 3 Terminated
Tominersen in Manifest Huntington's (GENERATION HD1)
Manifest Huntington's Disease
Halted March 2021 — exploratory analyses suggested potential harm from non-allele-specific HTT lowering. Reframed the field around earlier intervention + allele-selective targeting.
ClinicalTrials.gov ↗ - NCT04556656 Phase 3 Completed
Pridopidine in Huntington's Disease (PROOF-HD)
Manifest Huntington's Disease
Failed primary on cUHDRS; subgroup analyses suggested benefit in patients not on anti-dopaminergic background therapy.
ClinicalTrials.gov ↗ - NCT04127578 Phase 2 Active
AAV-GBA1 Gene Therapy in Parkinson's (PR001)
GBA1-mutant Parkinson's Disease
First systemic AAV gene therapy for a PD subtype; targets the most common genetic risk factor (GBA1 LoF).
ClinicalTrials.gov ↗ - NCT02623699 Phase 3 Completed
Tofersen in SOD1 ALS (VALOR)
SOD1-mutant ALS
Failed primary in VALOR; FDA accelerated approval April 2023 based on plasma neurofilament-light reduction. Surrogate-endpoint case study.
ClinicalTrials.gov ↗ - NCT04437511 Phase 3 Completed
Donanemab in Early Symptomatic Alzheimer's (TRAILBLAZER-ALZ 2)
Early Symptomatic Alzheimer's Disease
35% slowing on iADRS in low/medium tau population; 2nd FDA-approved disease-modifier (Kisunla, July 2024).
ClinicalTrials.gov ↗ - NCT03887455 Phase 3 Completed
Lecanemab (BAN2401) in Early Alzheimer's Disease (Clarity AD)
Early Alzheimer's Disease
Anti-amyloid monoclonal that achieved 27% slowing on CDR-SB; led to traditional FDA approval July 2023. Defined the post-amyloid AD-disease-modifying era.
ClinicalTrials.gov ↗
for agents scidex.list
Clinical trials listing — supports phase (phase_1|phase_2|phase_3|phase_4|na) and status (recruiting|active|completed|terminated|withdrawn) filter params via query string, cursor pagination, and sort by updated_at|start_date|completion_date.
POST /api/scidex/rpc
{
"verb": "scidex.list",
"args": {
"type": "clinical_trial"
}
}